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Abstract
Purpose Oral vitamin E is used in several childhood
diseases, but dosage recommendations differ. Few oral
products have a marketing authorization for therapeutic use
in children. Preliminary data indicate differences in bio-
availability among the various vitamin E compounds. Our
objective was to review published data on oral vitamin E
therapy in neonates and children in order to establish
dosage recommendations at a local level.
Methods A literature search was conducted, including
Medline Ovid, EMBASE (1980-Feb 2008), Cochrane
databases, product monographs, handbooks, and textbooks.
Results The main vitamin E compounds being used in
children are α-tocopherol, α-tocopheryl acetate, and
tocofersolan. The most data are available on tocopheryl
acetate, both in neonates and older children. In children
with malabsorption disorders, tocofersolan appears to
have an increased bioavailability compared to tocopherol
or tocopheryl acetate. Published data on pharmacokinetics
and dosages for clinical use are few and heterogeneous.
No pharmacokinetic studies were found for tocofersolan
in neonates and infants. There are few comparative
studies on pharmacokinetics, therapeutic use, and adverse
drug reactions (ADRs) in children. Dosages used in
clinical studies and dosage recommendations in hand-
books differ considerably.
Conclusions The differences in dosing recommendations in
children may be due to lack of systematic studies. Existing
published data on oral vitamin E do not provide a basis for
evaluation of dosage recommendations in children. Com-
parative clinical studies are required for scientific evalua-
tion of pharmacokinetics, dosage regimens, and efficacy/
ADR assessments in children.
Keywords VitaminE.Oraladministration.Liverdiseases.
Infant.Newborn.Child
Abbreviations
ADR(s) Adverse drug reaction(s)
ALP Alkaline phosphatase
BPD Bronchopulmonary dysplasia
NEC Necrotizing enterocolitis
PEG Polyethylene glycol
ROP Retinopathy of prematurity
TPGS Tocopheryl polyethylene glycol succinate
TPN Total parenteral nutrition
BNF British National Formulary
Introduction
Oral vitamin E is used in several childhood diseases, such
as for prevention of retinopathy of prematurity (ROP),
growth retardation, fat malabsorption (e.g., cystic fibrosis,
cholestatic diseases), and other chronic diseases in infants
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vitamin E is administered to alter the antioxidant status in
order to prevent free-radical damage in cell membranes, to
inhibit inflammatory processes by modulating cellular
signals, to regulate transcriptions, and to stimulate the
infants’ immune system [1]. In children with fat malab-
sorption, vitamin E is administered to prevent neuropathy,
gastrointestinal disturbances, and myopathy caused by
vitamin E deficiency.
Few oral products have been approved by regulatory
authorities, resulting in “off-label” or unlicensed use and
extempore pharmacy compounding [2–4]. Discussions with
physicians and pharmacists revealed different recommen-
dations on doses, formulations, and drug of choice. The
diversity was confirmed in a later survey [5]. Some oral
vitamin E products may contain excipients, such as
polyethylene glycol, propylene glycol, ethanol, or polysor-
bate 80, which have been associated with adverse drug
reactions in children.
“Vitamin E” is a common term for eight lipid-soluble
compounds: α-, β-, γ-, and δ-tocopherol, and α-, β-, γ-,
and δ-tocotrienol [6]. In humans, α-tocopherol is the most
abundant form in plasma [7]. Vitamin E compounds differ
in stereoisomerism, esterification, and biological activity
(Table 1)[ 6, 8].
Vitamin E undergoes passive diffusion from the small
intestine [7]. The absorption rates differ considerably
between individuals, ranging from 20–60%, depending on
pancreatic function, bile salts, concomitant fat intake, and
product properties [6, 9–11]. Preceding absorption, vitamin
E and food lipids form micelles in the presence of bile and
bile salts. The vitamin E compound tocofersolan has both
hydrophilic and lipophilic properties and may increase the
bioavailability of fat-soluble vitamin E in individuals
having a low degree of absorption [12]. The strength
conversion factor (Table 1) for tocofersolan is, however,
based on the tocopherol content of the molecule, regardless
of bioavailability. Vitamin E is not transformed and is
eliminated by fecal excretion or conjugation.
Our main aim was to review data on therapeutic use of
and recommendations for oral vitamin E therapy in
neonates and children.
Methods
To identify published studies, case reports, and infor-
mation on therapeutic use of oral vitamin E in children,
a literature search was carried out. Search terms in
Medline OVID and EMBASE were Vitamin e.mp, exp
Vitamin E/, tocofersolan.mp, or tpgs.mp; limited to human,
all child (birth to 18 years) or child.mp; administration,
oral or oral.mp; publication year 1980–February 2008.
Publications on other aspects than therapy, such as
supplements in formulas or total parenteral nutrition
(TPN), were excluded. Only articles written in English or a
Scandinavian language evaluating human subjects were
considered.
Therapy recommendations and product properties were
also found in handbooks, such as the British National
Formulary for Children (BNF for Children) [13], Medicines
for Children [14], Pediatric Dosage Handbook [11],
Neonatal Drug Formulary [15], Neofax [16], product
monographs, and formularies. In addition to the review
of clinical studies on the use of oral vitamin E in children,
data from the handbook recommendations are presented as
well.
Results
As this review focused on oral vitamin E therapy in
children, only studies including vitamin E doses, pharma-
cokinetics, and oral formulations were considered.
Clinical studies and case reports on oral vitamin E
therapy in children are few and heterogeneous regarding
the compounds being used, dosing, and indications. The
majority of the studies included a small number of
patients, and they rarely specified how doses were
chosen, either for prophylaxis or for treatment of current
deficiency. The exact name of the active substance was
rarely stated. Information on the content of excipients
was not always provided, and some studies did not
describe the formulation at all. Consequently, overall
statistical evaluations of dosing and formulation recom-
mendations for both neonates and older children have not
been feasible for this review.
Published data indicate that an esterified, synthetic
racemic mixture, all-rac-α-tocopheryl acetate (formerly
dl-α-tocopheryl acetate), and dl-α-tocopherol are com-
m o n l yu s e di nm e d i c i n a lp r o d u c t s( T a b l e2). A water-
soluble form, tocofersolan, has also been used [5].
Tocofersolan contains RRR-α-tocopherol with polyethyl-
ene glycol 1000 succinate [8]a n di sa l s oc a l l e d“d-α-
tocopheryl PEG 1000 succinate,”“ d-α-tocopheryl
polyethylene glycol succinate,”“ TPGS,” and “vitamin E
TPGS.”
Table 1 Content of common vitamin E compounds, in milligrams
(mg) and international units (IU) [6, 8]
Compound mg IU
dl-α-tocopheryl acetate 1 1.00
d-α-tocopheryl acetate 1 1.36
dl-α-tocopherol 1 1.10
d-α-tocopherol 1 1.49
Tocofersolan 1 0.39–0.45
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In this patient category, oral vitamin E may be used for
treatmentorforpreventionofvitaminEdeficiency,anemia,or
for prevention of ROP caused by oxygen therapy. However,
the interpretation of data is limited by several factors, as the
methodologies, choice of drugs and doses, outcomes, and
ADRassessments havebeenlessthanoptimal.VitaminE was
initiated as an oral formulation in only a few studies, and the
doses were heterogeneous. A Cochrane review on vitamin E
supplementation for prevention of morbidity and mortality in
preterm infants included 26 published studies that fulfilled the
Cochrane quality and entry criteria of primary and secondary
outcomes analysis; infants with gestational age less than
37 weeks or birth weight less than 2,500 g were included [1].
Most studies were carried out with other administration
forms, such as parenteral, intramuscular/intravenous, or
parenteral in combination with oral. Eight of these studies
refer to oral therapy alone and form the basis for our review
in this patient category (Table 2).
No recent studies on vitamin E treatment in neonates
were identified. The majority of the studies on oral vitamin
E administration in neonates describe the use of α-
tocopherol or α-tocopheryl acetate for prevention of
anemia. Only one study addresses prevention of ROP
[17]. For tocofersolan, we identified two small studies on
the effect on bilirubin levels [18, 19].
It is worth noting the diversity of doses, indications, and
choices of compounds in the studies. Vitamin E absorption
may differ among formulations [10]. Existing studies on
absorption were published several years ago, with subop-
timal designs and products no longer available. Systematic,
comparative dose-finding studies for any vitamin E com-
pound within this patient group were not identified. Serum
concentrations have been demonstrated to differ widely
even after equal doses [20, 21].
Dosing recommendations and indications differ among
handbooks (Table 3).
Oral vitamin E in children with liver or biliary tract disease
We did not identify any evidence-based review for these
patient categories. The clinical studies and case reports
have differing dosing approaches, choices of compound,
and outcome parameters (Table 4).
Neonates and children with bile duct atresia or chronic
intrahepatic cholestasis have insufficient bile secretion.
Vitamin E treatment is therefore indicated due to reduced
ability to dissolve dietary fat and vitamins. Serum concen-
trations may, however, still be lower than expected [22, 23].
Some studies describe the use of tocofersolan in children
with obstructive bile disease [24, 63, 65, 66], and a
medicinal product was recently approved by the European
Medicines Agency under exceptional circumstances [67].
The total daily dose is stated as 17 mg/kg of d-alpha-
tocopherol in the form of tocofersolan. Sokol and co-
workers analyzed serum concentrations in 22 children with
hepatic/biliary disease who had vitamin E deficiency [24].
All patients were switched from tocopheryl acetate to
tocofersolan, and all of them needed a significant dose
reduction in order to maintain the target serum concentra-
tion. On average, doses were reduced by 83% (range: 64.3–
93.5%). A larger study from the same authors included 60
children aged 0.5–20 years. All children needed a dose
reduction when tocopherol or tocopheryl acetate 70–200 IU
kg
−1 day
−1 was replaced with tocofersolan 20–25 IU kg
−1
day
−1 [65]. Dose reductions of 40–77% are also described
after changing from α-tocopherol to tocofersolan in children
with biliary stasis [63, 66]. Despite the paucity of data, these
results indicate that patients with absorption disturbances may
need considerable dose reduction when treated with tocofer-
solan compared to α-tocopherol or α-tocopheryl acetate.
Dosage recommendations in handbooks range from
“water-miscible vitamin E” 1I Uk g
−1 day
−1 [11] to 100–
200 mg α-tocopheryl acetate/day [13] (Table 3).
Other indications for oral vitamin E therapy
Vitamin E has also been used in children with diseases such
as abetalipoproteinemia (Table 3), cystic fibrosis [25–27],
β-thalassemia, sickle cell anemia [11, 13], inborn errors of
metabolism [28], epidermolysis bullosa [29], glucose-6
phosphate dehydrogenase deficiency [30], and focal seg-
mental glomerulosclerosis [31]. Many studies do not state
the rationale for the dose size, and dosing regimes are not
evaluated systematically. This is demonstrated by the cystic
fibrosis studies in children. Doses differed among the
studies: 5.5–47.4 IU kg
−1 day
−1,5 –10 mg kg
−1 day
−1, and
50–100 IU/day. The vitamin E compounds used in the
studies were described as tocopheryl acetate, tocopherol,
tocofersolan, or vitamin E. Despite this, dose recommen-
dations are listed in handbooks (Table 3).
Recently, vitamin E has been studied in children with
obesity-related liver disease [32–34]. Outcome parameters
included changes in laboratory findings such as amino-
transferases and alkaline phosphatase (ALP). A cohort
study of 11 children aged 8.3–14.3 years found a
normalization of serum aminotransferase and ALP after
treatment [32]. However, two other studies, including 28
and 90 children, respectively, found diet and/or exercise to
be more efficient than vitamin E therapy alone [33, 34].
Dosing implications for co-administration with other drugs
Tocopherol/tocopheryl acetate and tocofersolan appear to
differ in their potential for drug interactions. Tocofersolan
112 Eur J Clin Pharmacol (2010) 66:109–118Table 3 Summary of handbook dosing recommendations for oral vitamin E
Source Product Indications Dosages Comments
Neonatal Drug
Formulary [15]
Aquasol E
(tocopherol
acetate)
Investigational: treatment
or prevention of anemia
of prematurity
Adequate nutritional intake of
vitamin E as the only action
Monitor serum levels when
pharmacologic doses of vitamin E
are administered; liquid preparation
is very hyperosmolar and should
be diluted
All neonates with
birthweight <1,000 g
100 mg kg
−1 day
−1 beginning at
admission in the ward (adjusted to
maintain the level 0.5–3.5 mg/dL)
Retinopathy of prematurity
(ROP)
Prophylaxis: 25–50 units/day until
2–3 months, treatment:
50–200 units/day for 2 weeks Broncho-pulmonary
dysplasia (BPD)
Intraventricular hemorrhage
(IVH)
Neofax [16] Aquavit E
(tocopherol
acetate)
Prevention of vitamin E
deficiency; may be
indicated in babies
receiving erythropoietin
and high iron dosages
5–25 IU/day Hyperosmolar; contains polysorbate
80 and propylene glycol; higher
doses to reduce oxidant-induced
injury (ROP, BPD, IVH) remain
controversial
Pediatric Dosage
Handbook [11]
Aquasol E,
Aquavit E
Vitamin E deficiency Premature LBW neonates:
25–50 units/day
Normal levels within 1 week
of therapy
Prevention of vitamin E
deficiency
LBW neonates: 5 units/day,
full-term: 5 units/L formula
ingested
NEC has been associated with oral
administration of large dosages
(e.g., >200 units/day) of
hyperosmolar vitamin E preparation
in LBW neonates
Investigational: prevention
of ROP or BPD secondary
to oxygen therapy
15–30 units kg
−1 day
−1 to
maintain plasma levels at
1.5–2 μg/mL; neonates may need
as high as 100 units kg
−1 day
−1
Cystic fibrosis 100–400 units/day
Beta-thalassemia 750 units/day
Sickle cell anemia 450 units/day
Malabsorption syndrome 1 unit kg
−1 day
−1 of
water-miscible vitamin E
BNF for
Children [13]
Vitamin E
suspension
Vitamin E deficiency Neonate 10 mg kg
−1 day
−1 Consider dilution in neonates
due to high osmolality; increased
risk of NEC in preterm neonates
Child 1 month–18 years: 2–10 mg/kg
daily, up to 20 mg/kg has been used
Cystic fibrosis Child 1 month–1 year: 50 mg
once daily, adjusted as necessary
Child 1–12 years: 100 mg once
daily, adjusted as necessary
Child 12–18 years: 200 mg
once daily, adjusted as necessary
Cholestasis and severe
liver disease
Neonate: 10 mg/kg daily
Child 1 month–12 years: initially
100 mg daily, adjusted according
to response; up to 200 mg/kg
daily may be required
Child 12–18 years: initially
200 mg daily, adjusted according
to response; up to 200 mg/kg daily
may be required
Prevention of abnormally
low vitamin E levels in
abetalipoproteinaemia
Neonate: 100 mg/kg once daily
Child 1 month–18 years:
50–100 mg/kg once daily
LBW Low birth weight, NEC necrotizing enterocolitis
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114 Eur J Clin Pharmacol (2010) 66:109–118may increase the bioavailability of other drugs, such as
amprenavir [35], paclitaxel [36], vancomycin [37], and
cyclosporine [38], due to its combined lipophilic and
hydrophilic nature. In children with a liver transplant,
tocofersolan has been found to increase cyclosporine serum
concentrations significantly [39]. This may increase the risk
of ADRs when tocofersolan and cyclosporine are used
simultaneously [40]. Some studies suggest that vitamin E
may increase the risk of hemorrhages due to reduction of
prothrombin levels and may affect platelet function, partic-
ularly in patients with vitamin K deficiency, such as neonates
with sepsis, or in patients treated with antithrombotic
medicines such as warfarin and acetylsalicylic acid [13, 41,
42]. Decreased vitamin E plasma levels have been reported
after use of phenobarbital and phenytoin [43]. Drugs that
interfere with the reuptake of bile acids may reduce the
uptake of fat-soluble vitamins such as vitamin E [44].
Handbook information on drug interactions with vitamin
E is not consistent, and the information differs among
books and other literature.
Discussion
Overall, the body of evidence was limited due to the small
number of studies. The lack of supportive information on
oral vitamin E dosing recommendations in children is a
major concern. This review shows that oral vitamin E
dosing regimens for children differ considerably, and few
randomized clinical trials have been published. Information
on vitamin E pharmacokinetics in children is lacking, and
data regarding doses, compounds, and outcome parameters
are heterogeneous. There are no existing evaluations of
dose–effect relationships, therapeutic windows, safety
profiles, and optimum duration of therapy for the various
vitamin E compounds across age groups or disease states.
Many studies incorporate various forms of vitamin E
therapy in their treatment of neonates and older children,
such as oral, intravenous, and intramuscular administration
and as supplement in total parenteral nutrition. Consequently,
thereisverylittledocumentationtosupportanevidence-based
choice of oral therapeutic dose or compound.
Vitamin E compounds may differ in biological activity
and bioavailability. Most clinical data in children are
available for α-tocopherol or tocopherol esters, such as
α-tocopheryl acetate. While a tocofersolan product recently
received a marketing authorization in the EU for use in
children with cholestasis, this product is contraindicated in
premature infants. In newborns, most evaluations on
efficacy and safety are based on studies with intravenous
or intramuscular tocopheryl acetate. Assessment on the risk/
benefit profile has not yet been done for oral vitamin E in
neonates and children.
Tocofersolan may have increased bioavailability com-
pared to other vitamin E compounds. This has resulted in
therapeutic serum levels despite considerable dose reduc-
tions when switching from tocopheryl acetate in children
with malabsorption diseases [24, 65]. Conversely, absorp-
tion of tocopheryl acetate in healthy adults may be similar
or even superior to tocofersolan [45]. A change of therapy
from α-tocopheryl acetate to tocofersolan may have
consequences for dosing recommendations and the ADR
profile, but it is not known whether this is the case for all
patient groups or whether differences in intestinal absorp-
tion are less pronounced in infants without malabsorption
disorders. The pharmacokinetic properties of tocofersolan
indicate that therapeutic monitoring may be advisable in
children to avoid adverse reactions.
The relative biological activities of vitamin E com-
pounds have been determined by a rat model, founded on
the fact that vitamin E depletion after conception causes
death and embryo resorption [6]. However, the rat model
cannot be used to detect differences in biological activity or
bioavailability in immature, human intestines, such as in
premature babies, sick neonates, or in patients with
gastrointestinal disturbances. To our knowledge, the mg/
IU ratio for tocofersolan is based on a calculation of the
tocopherol content of the molecule and not the bioavail-
ability of the molecule.
Toxicity and ADRs, such as sepsis, NEC, and hemor-
rhages have been reported after vitamin E therapy [1]. The
risk of such events appears to be associated with low birth
weight and serum levels above 3.5 mg/dL. No follow-up
studies in neonates or older children have been found.
Some oral vitamin E products may contain excipients,
such as polyethylene glycol, propylene glycol, ethanol, or
polysorbate 80, which have been associated with ADRs in
children. Few vitamin E products have a marketing
authorization for oral administration in children. Therefore,
extempore pharmacy compounding may be the only option.
There are, however, few product specifications. In the
1980s, reports of deaths and serious ADRs, including
thrombocytopenia and kidney and liver failure, were linked
to the use of an intravenous vitamin E product [46] and
may have been caused by dose-related toxicity of α-
tocopherol, the emulsifier polysorbate or both. Oral
administration of vitamin E has been associated with an
increased risk of NEC, possibly related to dose, polysorbate
content, or hyperosmolar products [47]. The polyethylene
glycol component of tocofersolan may put children at risk
as it accumulates in patients with immature kidneys [65]. In
Norway, an extempore formulation containing 20% alcohol,
originally intended for veterinary use, has been widely used
“off-label” in neonates and older children [5]. The alcohol
content of 60 mg 96% ethanol per 15 mg tocopheryl acetate
in a 1,000-g premature baby is equivalent to 10 mL 45%
Eur J Clin Pharmacol (2010) 66:109–118 115ethanol in a 70-kg adult. While data on pediatric alcohol
exposure due to excipients are limited, there is a potential
risk of adverse effects, especially in neonates and premature
infants [48].
Several handbooks carry a warning for hyperosmolar
products. However, information on the osmolality of the
various pharmacy-compounded products is not provided.
The choice offormulation should be based on the principle
of suitability for the most vulnerable patients (premature
neonates), degree of documentation for pediatric patients,
pharmacokinetic predictability/reliability, and suitable
strengths for the intended patient groups. The most obvious
factor for achieving a suitable formulation would be to keep
the content of alcohol and other excipients to a minimum and
to make a critical appraisal of the need for each ingredient.
Regarding the active ingredient, both tocopheryl acetate
and tocofersolan have advantages and disadvantages. Using
tocofersolan eliminates the need for ethanol. In some patients,
the bioavailability may be more predictable. The disadvan-
tages of tocofersolan are the lack of documentation, unclari-
fied dosage equivalency, and presence of polyethylene glycol.
Two different formulations may be necessary, due to the
differences in doses between premature neonates and school-
age hepatobiliary patients/post-liver transplant children.
Increasingdoseswithagemaynecessitateincreasingstrengths
and corresponding increases in alcohol content to increase the
solubility. This would represent a lesser problem in older
children than in the smallest ones. Sick neonates having
septicemia and other concurrent diseases have several battles
to fight. The metabolic pathways for drugs are under
development (transition from intrauterine to extrauterine life),
they have reduced capacity for drug metabolism, and
ultimately the degree of the disease may affect drug metabo-
lism to a greater extent at this time than for older children.
In summary, the evidence regarding the use of oral
vitamin E in children is limited and largely of poor
methodological quality. Several types of studies are needed.
A survey study would increase our knowledge of current
therapeutic practice. The objective should be to discover to
what extent vitamin E is being used for neonates and older
children in European countries, the U.S.A., and Japan, for
which patient groups, and which products and doses are the
most commonly used. In addition, indications for prescribing
the particular drug, existing guidelines in hospitals, and the
basis for existing practice could be examined. Furthermore,
there is a need for well-designed pharmacokinetic studies
including different formulations of tocopherol, tocopheryl
acetate, and tocofersolan. The studies should include relevant
patient groups such as premature neonates, patients with
congenital bile atresia before and after surgical therapy, and
children after liver transplantation.
At present, most clinical data refer to tocopheryl acetate.
Randomized, controlled trials should be done to examine
the optimum doses and therapeutic equivalency of tocoph-
erol/tocopheryl acetate and tocofersolan. There are, how-
ever, certain methodological challenges regarding choice of
treatment and control groups. When treatment is regarded
as essential, placebo controls would be unethical. To our
knowledge some hospitals in Europe do not include oral
vitamin E treatment in, e.g., neonates on respirators or those
on oxygen therapy. Consequently, it would be possible to
do comparative studies. Comparison of different therapy
regimens with the various forms of vitamin E might be a
possible option in children already on therapy. Other options
includecaseseriesfromhospitalsorcohortstudies,depending
on the information desired. Comparisons of patients from two
hospitals with different treatment regimens would have to be
examined carefully due to possible confounding factors. Data
collection from patients who currently receive an oral vitamin
E product, including therapeutic monitoring, would be the
most readily available method to gather readily accessible
material. When a clinical, comparative study is feasible, we
would suggest monitoring outcome parameters as analyzed in
the Cochrane metaanalysis with primary outcomes being
mortality/survival and long-term morbidity, and secondary
outcomes being bronchopulmonary dysplasia, patent ductus
arteriosus,sepsis,ROP,NEC,hemoglobin,bilirubin,platelets,
and coagulation parameters. Visual assessments at 3 and
6 months should be included.
Conclusions
Oral vitamin E compounds have been used for decades to
treat a number of conditions in children. There are few data
to suggest solid guidelines on oral vitamin E therapy. The
present data do not provide sufficient evidence of dosing
and products to make recommendations for oral vitamin E
use in children. Most data are available on therapeutic use
of α-tocopherol or tocopherol esters, such as α-tocopheryl
acetate.
There are no systematic safety data or documentation on
long-term effects. Extensive use of oral vitamin E in
premature infants and neonates solely for prophylactic
purposes needs to be evaluated. Systematic evaluations
based on clinical trials would be a better foundation for
therapeutic use in premature infants and neonates, regard-
ing both indication for therapy and prevention. Further
research, including comparative, dose-finding studies, is
required to ensure evidence-based dosing recommendations
for neonates and older children.
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